Xenetic Biosciences, Inc. (XBIO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Xenetic Biosciences reported revenue of $3.0M, up 19.0% from $2.5M the year before. Net income was -$2.7M (a -90.1% net margin), or -$1.58 per diluted share. Operating margin was -95.2%. Operating activities generated -$2.3M of cash. At fiscal year end, Xenetic Biosciences held $8.4M in total assets against $968,025 in total liabilities.
Open the full interactive Xenetic Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Xenetic Biosciences Key Stats
| Share Price | $2.10 |
|---|---|
| Market Cap | $4.8M |
| Revenue YoY Growth | +19.0% |
| 52-Week Range | $2.02 – $5.37 |
| Shares Outstanding | 2.3 million (basic, 2026 Q2) |
Xenetic Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $436,942 | $1.2M | $1.7M | $2.5M | $2.5M | $3.0M |
| Operating Income | -$13.9M | -$5.7M | -$6.7M | -$4.5M | -$4.2M | -$2.8M |
| Pre-Tax Income | -$13.8M | -$5.6M | -$6.6M | -$4.1M | -$4.0M | -$2.7M |
| Income Tax | -$2.9M | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$10.9M | -$5.6M | -$6.6M | -$4.1M | -$4.0M | -$2.7M |
| Diluted EPS | -$17.00 | -$5.50 | -$4.60 | -$2.71 | -$2.57 | -$1.58 |
Xenetic Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.0M | $766,296 | $806,923 | $660,601 |
| Net Income | -$509,940 | -$579,076 | -$456,382 | -$929,695 |
| Diluted EPS | -$0.33 | -$0.34 | -$0.20 | -$0.41 |
Xenetic Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Current Assets | $12.4M | $18.7M | $13.7M | $9.6M | $6.6M | $8.0M |
| Total Assets | $13.2M | $19.8M | $14.7M | $10.6M | $6.9M | $8.4M |
| Current Liabilities | $936,928 | $1.4M | $1.1M | $809,585 | $894,263 | $968,025 |
| Total Liabilities | $963,971 | $1.4M | $1.1M | $809,585 | $894,263 | $968,025 |
| Shareholders' Equity | $12.2M | $18.4M | $13.6M | $9.8M | $6.0M | $7.4M |
Xenetic Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$4.3M | -$4.7M | -$4.6M | -$4.1M | -$2.8M | -$2.3M |
| Cash From Investing | $0 | — | -$500,000 | $0 | — | — |
| Cash From Financing | $5.4M | $11.5M | $0 | — | — | $4.0M |
Figures from Xenetic Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Xenetic Biosciences financials page for every line item.
Xenetic Biosciences Company Profile
| Ticker | XBIO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Framingham, Massachusetts |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001534525 |
Frequently Asked Questions
What was Xenetic Biosciences' revenue in fiscal 2025?
Xenetic Biosciences (XBIO) reported revenue of $3.0M for fiscal 2025.
What is Xenetic Biosciences' annual revenue history?
Xenetic Biosciences' annual revenue by fiscal year: 2020: $436,942; 2021: $1.2M; 2022: $1.7M; 2023: $2.5M; 2024: $2.5M; 2025: $3.0M.
What was Xenetic Biosciences' net income in fiscal 2025?
Xenetic Biosciences reported net income of -$2.7M for fiscal 2025.
What was Xenetic Biosciences' earnings per share (EPS) in fiscal 2025?
Xenetic Biosciences' diluted EPS was -$1.58 for fiscal 2025 (adjusted for any later stock splits).
What was Xenetic Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Xenetic Biosciences reported revenue of $660,601.
How many shares of Xenetic Biosciences are outstanding?
Xenetic Biosciences reported a weighted average of 2.3 million basic shares outstanding in 2026 Q2.
What is Xenetic Biosciences' market cap?
Based on its latest closing price, Xenetic Biosciences (XBIO) has a market capitalization of about $4.8M.
When does Xenetic Biosciences' fiscal year end?
Xenetic Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Xenetic Biosciences headquartered?
Xenetic Biosciences lists its business address in Framingham, Massachusetts in its SEC filings.